**Part LC480 clinical annotation**: Patient characteristics of the samples used for the high-throughput MSP screening on the Roche LC480. PatientID is a unique patient number, the group indicates the risk. Clinical characteristics given are the age at diagnosis in months, International Neuroblastoma Staging System (INSS) stage, *MYCN* status (0 is non-amplified/single copy and 1 is amplified), follow-up time (FU) in days after diagnosis, and overall survival (OS) and event-free survival (EFS) time in days after diagnosis. OS indicates whether the patient was alive (0) at the last known FU or died of disease (1). Similar for EFS, indicating events such as relapse or progression. Segmental aberrations for chromosome 1p, 11q and 17q are indicated with normal, partial loss (PL), whole loss (WL), partial gain (PG) or whole gain (WG). Empty cells represent missing values.

**Part LC480 overview annotation**: Summary of the clinical characteristics of the 89 primary neuroblastoma samples used in the high-throughput MSP screening. HR-DOD: high-risk deceased patients, HR-SURV: high-risk patients alive for at least 1000 days follow-up, LR-SURV: low-risk patients alive for at least 1000 days follow-up, and INSS: International Neuroblastoma Staging System.

**Part LC480 assays**: MSP assays used in the high-throughput MSP screening on the Roche LC480. For each tested gene, the assay name(s) and corresponding forward and reverse primer(s) (5’ to 3’) are indicated, as well as the genomic location of the amplicon on the hg19 reference genome.

**Part LC480 results**: Results of the high-throughput MSP screening on the Roche LC480. For each assay and for each sample, the methylation call (dark blue is methylated, green unmethylated) is given. The patient samples are subdivided into three prognostic groups (LR-SURV, HR-DOD and HR-SURV). HR-DOD: high-risk deceased patients, HR-SURV: high-risk patients alive for at least 1000 days follow-up, LR-SURV: low-risk patients alive for at least 1000 days follow-up, CL: cell line, Neg: negative control (HCT-116 DKO cell line), and NTC: no template control.

**Part LC480 overview results**: Summary of the MSP results of the high-throughput study. The number of methylated samples for a particular MSP assay within each prognostic group and for the entire sample set is given (percentage of methylated samples between brackets). Assays are ranked descending on the number of overall methylated samples. Assays discussed in more detail in the results section are indicated in grey. HR-DOD: high-risk deceased patients, HR-SURV: high-risk patients alive for at least 1000 days follow-up, LR-SURV: low-risk patients alive for at least 1000 days follow-up.

**Part Group associations**: Detailed information on a selection of assays, differentially methylated between prognostic groups (per prognostic group and per combination of risk factors). The number (percentage) of methylated samples in each stratum is given. HR-DOD: high-risk deceased patients, HR-SURV: high-risk patients alive for at least 1000 days follow-up, LR-SURV: low-risk patients alive for at least 1000 days follow-up.

**Part Risk factor associations**: Detailed information on a selection of assays, differentially methylated between neuroblastoma risk factors (per (combination of) risk factors). The number (percentage) of methylated samples in each stratum is given. HR-DOD:

high-risk deceased patients, HR-SURV: high-risk patients alive for at least 1000 days follow-up, LR-SURV: low-risk patients alive for at least 1000 days follow-up.

**Part Heatmap**: Hierarchical clustering based on the MSP data of the 89 primary neuroblastoma tumor samples. This analysis reveals two clusters, indicated with group 1 and group 2, which predominantly distinguish high-risk and low-risk neuroblastoma patient samples. Each sample is assigned to a prognostic group (LR-SURV, HR-DOD and HR-SURV). HR-DOD: high-risk deceased patients, HR-SURV: high-risk patients alive for at least 1000 days follow-up and LR-SURV: low-risk patients alive for at least 1000 days follow-up.

**Part KM number**: Kaplan-Meier plot: overall survival in the samples of the high-throughput MSP screening according to the number of methylation events. The purple line indicates patients with 0 to 16 methylation events, the red line patients with 16 to 27 methylation events. This 16 methylation events cut-off was used, as the average number of methylation events in one sample is 16. The p-value is determined using a log-rank test (Mantel-Cox). Time is indicated in days, starting from diagnosis.

| PatientID | Group | Age at diagnosis (months) | INSS Stage | *MYCN* | Chr1p | Chr17q | Chr11q | FU time (days) | OS time (days) | EFS time (days) | OS | EFS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | HR-DOD | 146 | 4 | 1 | PL |  | WL | 754 | 754 | 281 | 1 | 1 |
| 41 | HR-DOD | 51 | 4 | 0 | normal |  | WL | 569 | 569 | 397 | 1 | 1 |
| 384 | HR-DOD | 28 | 4 | 0 | normal |  | WL | 966 | 966 | 890 | 1 | 1 |
| 513 | HR-DOD | 30 | 4 | 1 | PL |  | normal | 167 | 167 | 142 | 1 | 1 |
| 610 | HR-DOD | 35 | 4 | 1 | normal |  | WL | 850 | 850 | 782 | 1 | 1 |
| 906 | HR-DOD | 19 | 3 | 1 | PL | PG | normal | 216 | 216 | 53 | 1 | 1 |
| 917 | HR-DOD | 92 | 4 | 1 | PL | PG | normal | 485 | 485 | 439 | 1 | 1 |
| 928 | HR-DOD | 12 | 4 | 1 | PL | PG | normal | 412 | 412 | 286 | 1 | 1 |
| 1015 | HR-DOD | 42 | 4 | 0 | normal |  | WL | 581 | 581 | 449 | 1 | 1 |
| 1378 | HR-DOD | 155 | 4 | 0 | normal |  | WL | 4910 | 4910 | 3793 | 1 | 1 |
| 1467 | HR-DOD | 0 | 4 | 1 | normal | PG | normal | 1 | 1 | 1 | 1 | 1 |
| 1473 | HR-DOD | 8 | 4 | 1 | PL | PG | normal | 239 | 239 | 116 | 1 | 1 |
| 1477 | HR-DOD | 79 | 4 | 1 | PL | PG | normal | 1246 | 1246 | 898 | 1 | 1 |
| 1507 | HR-DOD | 14 | 4 | 1 |  |  |  | 285 | 285 | 273 | 1 | 1 |
| 1517 | HR-DOD | 35 | 4 | 0 | normal | PG | PL | 547 | 547 | 433 | 1 | 1 |
| 1520 | HR-DOD | 40 | 4 | 1 | normal | PG | PL | 1279 | 1279 | 552 | 1 | 1 |
| 1522 | HR-DOD | 23 | 3 | 1 | PL | PG | normal | 728 | 728 | 594 | 1 | 1 |
| 1527 | HR-DOD | 108 | 4 | 1 | PL | normal | normal | 319 | 319 |  | 1 | 1 |
| 1648 | HR-DOD | 53 | 4 | 0 | normal | PG | PL | 1221 | 1221 | 341 | 1 | 1 |
| 1781 | HR-DOD | 41 | 4 | 1 |  |  |  | 679 | 679 | 651 | 1 | 1 |
| 2859 | HR-DOD | 63 | 3 | 1 |  |  |  | 4493 | 4493 | 3861 | 1 | 1 |
| 2865 | HR-DOD | 91 | 4 | 0 |  |  |  | 1353 | 1353 | 1353 | 1 | 1 |
| 2866 | HR-DOD | 80 | 4 | 0 |  |  |  | 1300 | 1300 | 786 | 1 | 1 |
| 2869 | HR-DOD | 72 | 4 | 0 |  |  |  | 1380 | 1380 | 1011 | 1 | 1 |
| E061 | HR-DOD | 31 | 4 | 0 | normal | PG | PL | 1445 | 1445 | 497 | 1 | 1 |
| E069 | HR-DOD | 59 | 4 | 0 | normal | PG | PL | 2836 | 2836 | 2016 | 1 | 1 |
| E282 | HR-DOD | 17 | 4 | 1 | PL | PG | normal | 711 | 711 | 433 | 1 | 1 |
| E290 | HR-DOD | 6 | 4 | 1 | PL | normal | normal | 539 | 539 | 531 | 1 | 1 |
| 526 | HR-SURV | 26 | 4 | 1 | normal | PG | normal | 2009 | 2009 |  | 0 | 0 |
| 915 | HR-SURV | 16 | 4 | 1 | PL |  | normal | 1985 | 1985 |  | 0 | 0 |
| 1017 | HR-SURV | 22 | 3 | 1 | PL | PG | normal | 1758 | 1758 |  | 0 | 0 |
| 1148 | HR-SURV | 27 | 3 | 1 |  |  |  | 1212 | 1212 |  | 0 | 0 |
| 1384 | HR-SURV | 16 | 3 | 1 |  |  |  | 1620 | 1620 |  | 0 | 0 |
| 1385 | HR-SURV | 31 | 3 | 1 |  |  |  | 1185 | 1185 |  | 0 | 0 |
| 1431 | HR-SURV | 23 | 4 | 1 | PL | PG | normal | 953 | 953 |  | 0 | 0 |
| 1501 | HR-SURV | 131 | 4 | 0 |  |  |  | 1558 | 1558 | 1558 | 0 | 1 |
| 1508 | HR-SURV | 6 | 2 | 1 |  |  |  | 1449 | 1449 |  | 0 | 0 |
| 1521 | HR-SURV | 38 | 4 | 1 | normal | WG | WL | 2163 | 2163 |  | 0 | 0 |
| 1524 | HR-SURV | 23 | 3 | 1 | PL | PG | WL | 2387 | 2387 |  | 0 | 0 |
| 1647 | HR-SURV | 10 | 2 | 1 |  |  |  | 2136 | 2136 |  | 0 | 0 |
| 1789 | HR-SURV | 25 | 3 | 1 |  |  |  | 5616 | 5616 |  | 0 | 0 |
| 1793 | HR-SURV | 33 | 3 | 1 |  |  |  | 1176 | 1176 |  | 0 | 0 |
| 1794 | HR-SURV | 33 | 3 | 1 |  |  |  | 5096 | 5096 |  | 0 | 0 |
| 1800 | HR-SURV | 71 | 4 | 1 |  |  |  | 1862 | 1862 |  | 0 | 0 |
| 2855 | HR-SURV | 32 | 3 | 1 |  |  |  | 1386 | 1386 |  | 0 | 0 |
| 2856 | HR-SURV | 41 | 3 | 1 |  |  |  | 1330 | 1330 | 834 | 0 | 1 |
| 2857 | HR-SURV | 29 | 3 | 1 |  |  |  | 1295 | 1295 |  | 0 | 0 |
| 2860 | HR-SURV | 66 | 3 | 1 |  |  |  | 1489 | 1489 |  | 0 | 0 |
| 2861 | HR-SURV | 19 | 3 | 1 |  |  |  | 1514 | 1514 | 445 | 0 | 1 |
| 2862 | HR-SURV | 43 | 2 | 1 |  |  |  | 1161 | 1161 |  | 0 | 0 |
| 2863 | HR-SURV | 11 | 4 | 1 |  |  |  | 1237 | 1237 |  | 0 | 0 |
| 2864 | HR-SURV | 26 | 4 | 0 |  |  |  | 1310 | 1310 |  | 0 | 0 |
| 2867 | HR-SURV | 46 | 4 | 0 |  |  |  | 1112 | 1112 |  | 0 | 0 |
| E458 | HR-SURV | 7 | 4 | 0 | normal | PG | PL | 2284 | 2284 | 1399 | 0 | 1 |
| E579 | HR-SURV | 13 | 4 | 0 | normal | PG | PL | 3534 | 3534 |  | 0 | 0 |
| E598 | HR-SURV | 49 | 4 | 0 | PL | PG | PL | 3219 | 3219 |  | 0 | 0 |
| E685 | HR-SURV | 14 | 4 | 0 | normal | PG | PL | 3011 | 3011 |  | 0 | 0 |
| E700 | HR-SURV | 20 | 4 | 0 | PL | normal | PL | 1536 | 1536 |  | 0 | 0 |
| 410 | LR-SURV | 2 | 1 | 0 | normal | WG | WL | 2910 | 2910 |  | 0 | 0 |
| 414 | LR-SURV | 3 | 1 | 0 |  |  |  | 2951 | 2951 |  | 0 | 0 |
| 530 | LR-SURV | 2 | 1 | 0 | normal | WG | normal | 2216 | 2216 |  | 0 | 0 |
| 566 | LR-SURV | 0 | 2a | 0 | normal | WG | WL | 1615 | 1615 |  | 0 | 0 |
| 744 | LR-SURV | 16 | 2b | 0 | normal | WG | normal | 1850 | 1850 |  | 0 | 0 |
| 809 | LR-SURV | 0 | 1 | 0 | normal | WG | normal | 2904 | 2904 |  | 0 | 0 |
| 820 | LR-SURV | 11 | 2 | 0 |  |  |  | 4794 | 4794 |  | 0 | 0 |
| 822 | LR-SURV | 13 | 1 | 0 | normal |  |  | 1153 | 1153 |  | 0 | 0 |
| 823 | LR-SURV | 4 | 1 | 0 | normal |  | normal | 1090 | 1090 |  | 0 | 0 |
| 858 | LR-SURV | 1 | 1 | 0 | normal |  | normal | 1562 | 1562 |  | 0 | 0 |
| 912 | LR-SURV | 0 | 1 | 0 |  |  |  | 2904 | 2904 |  | 0 | 0 |
| 916 | LR-SURV | 10 | 1 | 0 | normal | WG | WL | 3830 | 3830 |  | 0 | 0 |
| 926 | LR-SURV | 1 | 1 | 0 | normal | WG | WL | 1861 | 1861 |  | 0 | 0 |
| 929 | LR-SURV | 3 | 1 | 0 | normal | WG | WL | 1076 | 1076 |  | 0 | 0 |
| 1028 | LR-SURV | 3 | 1 | 0 | normal |  |  | 2932 | 2932 |  | 0 | 0 |
| 1038 | LR-SURV | 11 | 2 | 0 |  |  |  | 1071 | 1071 |  | 0 | 0 |
| 1039 | LR-SURV | 8 | 3 | 0 |  |  |  | 1394 | 1394 |  | 0 | 0 |
| 1377 | LR-SURV | 3 | 2 | 0 | normal |  | normal | 2511 | 2511 |  | 0 | 0 |
| 1395 | LR-SURV | 1 | 1 | 0 |  |  |  | 2027 | 2027 |  | 0 | 0 |
| 1468 | LR-SURV | 7 | 2 | 0 | WG | WG | WL | 1808 | 1808 |  | 0 | 0 |
| 1476 | LR-SURV | 22 | 2 | 0 |  |  |  | 2075 | 2075 |  | 0 | 0 |
| 1478 | LR-SURV | 1 | 1 | 0 |  |  |  | 1066 | 1066 |  | 0 | 0 |
| 1479 | LR-SURV | 3 | 1 | 0 | normal | WG | normal | 1156 | 1156 |  | 0 | 0 |
| 1486 | LR-SURV | 12 | 1 | 0 | normal | WG | normal | 2328 | 2328 |  | 0 | 0 |
| 1487 | LR-SURV | 7 | 1 | 0 |  |  |  | 1463 | 1463 |  | 0 | 0 |
| 1488 | LR-SURV | 2 | 2 | 0 |  |  |  | 1827 | 1827 |  | 0 | 0 |
| 1492 | LR-SURV | 0 | 1 | 0 |  |  |  | 1316 | 1316 |  | 0 | 0 |
| 1528 | LR-SURV | 10 | 1 | 0 |  |  |  | 1622 | 1622 |  | 0 | 0 |
| 1531 | LR-SURV | 2 | 1 | 0 | normal | WG | normal | 1593 | 1593 |  | 0 | 0 |
| 1612 | LR-SURV | 6 | 1 | 0 | normal | WG | normal | 2271 | 2271 |  | 0 | 0 |
| 1650 | LR-SURV | 1 | 2 | 0 | normal | WG | WL | 1264 | 1264 | 187 | 0 | 1 |

LC480 clinical annotation

| Characteristic | Classes | Count (percentage) |
|---|---|---|
| **Risk Classification** | HR-DOD | 28/89 (31%) |
| | HR-SURV | 30/89 (34%) |
| | LR-SURV | 31/89 (35%) |
| **INSS Stage** | 1 | 21/89 (24%) |
| | 2 | 12/89 (13%) |
| | 3 | 17/89 (19%) |
| | 4 | 39/89 (44%) |
| ***MYCN*** | Not amplified | 50/89 (56%) |
| | Amplified | 39/89 (44%) |
| **Age** | Age at diagnosis > 12 months | 53/89 (60%) |
| | Age at diagnosis < 12 months | 36/89 (40%) |

LC480 overview annotation

| Name | Forward primer | Reverse primer | Genomic location |
|---|---|---|---|
| TGFBI_18014 | ATTTTGGCGGGTTTCGTTA | ACTCGACTTACCCGTACTAAC | chr5:135364804-135364889 |
| ACTB_1 | TAGGGAGTATATAGGTTGGGGAAGTT | AACACACAATAACAAACACAAATTCAC | chr7:5571799-5571902 |
| TNFRSF10D_23780 | TCGGGGTATAAAAGCGGAG | ATCAAAAATCGTCCCCGTAA | chr8:23021486-23021578 |
| KRT19_83159 | GGTCGCGGGTATAAAAGGC | CATAACGAAACGAAACACGAAC | chr17:39684496-39684598 |
| KRT19_61596 | TTATAGTTATCGTTAGTCGTCGGT | ACCCCCGTAAATACTAAACGC | chr17:39684382-39684491 |
| TNFRSF10A_65529 | GGTATTTAGTAGGCGTTCGGTG | ACTCGCCCGATAATAACGAAA | chr8:23082862-23082978 |
| RARRES1_57581 | GCGAAATCGTAGGGGAAAC | ATAAAAACGCCTCCCCGAAA | chr3:158450497-158450595 |
| CYGB_83388 | TCGTGTGGGTAAGAGTTAATGTCG | CTCCGCCGTAACCTACGAA | chr17:74533911-74534004 |
| FBN2_18150 | TCGGAGTTTTATAGGGTAACGAA | CTCTTACTAACCGCACGCC | chr5:127873815-127873902 |
| PDLIM4_4 | GGCGTTTAGGTTAATTTTTCGT | CGATCCCATATCTAAAACCGA | chr5:131593549-131593644 |
| CXCR4_70046 | GCGTGGGTGTAGTGGGTAGTC | TAAAAACCTCCAAACGATAAACACG | chr2:136874383-136874463 |
| RBP4_24106 | GGTCGTTTCGTTGTTTTATAGC | GCGTTATACAAATACCCCCG | chr10:95361003-95361106 |
| RBP1_83281 | TGCGTTCGTTTTCGTTAAGC | CTAAATTCCCAACGCGCAC | chr3:139258517-139258597 |
| NPTX2_57773 | TTTTAGTTTGTGACGTTCGCGTT | TAAAACTCTCGAAAACCTCGACT | chr7:98246269-98246349 |
| PPIC_69739 | CGGTTGTTGTTATTTTTCGTGT | CTCTCGATCACCTTAACCGTC | chr5:122372192-122372305 |
| NPY_18477 | TTTTATTCGATGGCGTTGTC | AACAACTAACGATCTCCCTACGA | chr7:24324196-24324288 |
| FAS_18143 | TTTTTGATTATCGGGGTTTTTC | AACCAAATCACTCGTAAACCG | chr10:90750369-90750484 |
| EDNRB_1 | CGTTTTAGTTAAGCGTGCGTG | CGAAATATAAAAATTCCCCTACGA | chr13:78493099-78493204 |
| DPP4_74913 | TGGCGAAGAGGTTTTTATAGTTC | TACGCTCCTTCTCTAAACGCTC | chr2:162930431-162930534 |
| FBN2_18151 | TTGGAGATTTCGATAGAGCGT | AAACTACCGACTACACCTCCG | chr5:127873440-127873551 |
| NTRK1_1259 | TTTTACGGGATTAGATTTAAGTTTCGT | AACGAAAACGCGATAACCTT | chr1:156783919-156784031 |
| NEBL_1678 | TTTTGGGACGTAGGTTTTCG | AACCGTCTCTACTACGCG | chr10:21463545-21463628 |
| PDE4DIP_1689 | GCGTTTCGTCGGGTTTAT | AACTCCCGACTAACTCCG | chr1:145075684-145075799 |
| PLXNC1_1397 | CGAGTGCGGTAATTATCGTTATT | CCGTCTTAACCCGACTATAAAAC | chr12:94533764-94533877 |
| PRPH_1409 | GATTTGTTCGACGTTGTTAATCG | CTCGCACGTTAAACTCTAAATCTAA | chr12:49690936-49691035 |
| CNR1_1699 | AAATGAACGTTAAGGCGGTTATAA | AATCGCACGATTTCCACC | chr6:88877266-88877378 |
| ADRB2_1431 | TTTTATCGTTTTGGTTATCGTGTTTG | TAATAACCGTCTACAAACGCTCG | chr5:148206516-148206599 |
| QPCT_1446 | CGTAGTTGTATTTGAGCGGTT | ATAAAACGCCGATACCTAAACTAAAA | chr2:37572011-37572131 |
| mir-663_1705 | TTCGTCGTTTATTGTGGTCG | CAACCATCGCTCGCTATC | chr20:26189216-26189327 |
| mir-671_1465 | GAGTTAGAGCGACGGTATTTTG | CTTCGAAACCACGTCCATAAA | chr7:150935098-150935194 |
| HIST1H3C_1491 | AATAGTTCGTAAGTTTATCGGCG | ATACCCGAACGATAACGATAAAATTT | chr6:26045655-26045775 |
| ACSS3_1504 | TTTTAGTGGTTTCGGGTTCG | ACCGAAACTACGAAATAAATCTTATACTC | chr12:81472005-81472108 |
| KCND2_1525 | TTTTAGTGGTTTCGGGTTCG | ACCGAAACTACGAAATAAATCTTATACTC | chr12:81472005-81472108 |
| GNAS_1532 | TCGAATCGGAATTTGATTACGAG | CTCGATCTCGCTCTCGAT | chr20:57415399-57415509 |
| COL6A3_1719 | TGTATTTCGGGCGGTAGT | ACAAAACGAATCCCGAATAAATTTTAAA | chr2:238322242-238322326 |
| TRIM36_1727 | TAAACGTGGTGATTTCGAGTG | AATCGCACACTTCGAACC | chr5:114515219-114515317 |
| SHOX2_1738 | CGTTCGTTATCGGAGGTTG | GAAATCGCACGAACACAAAC | chr3:157821378-157821486 |
| C3orf70_1749 | GTTACGCGATGTATTCGGTT | CGAATAACACTAACCACCGAAAA | chr3:184871092-184871212 |
| ANKRD43_1611 | GGTTGTATTGTACGGTTACGAG | AAAACCGAACCGCAAATACTAATA | chr5:132150485-132150603 |
| PCDHA6_16211 | TTGGTGTCGCGTTTGTTTA | CGATCCGAAAATTCACAAACAAAATA | chr5:140207850-140207947 |
| GRB10_1759 | TTAGTTTACGATAGAGTACGGGG | ATAAACGAACTATTTAAAACGCACAAAA | chr7:50861529-50861646 |
| APOE_1643 | CGTTTGGACGAGGTGAAG | AACCTCGACCTACAAACGTA | chr19:45412288-45412375 |
| PTGER4_1659 | TGCGTCGTATTTCGTTGG | GCTAAAACGCGACAAAACTAAAA | chr5:40681747-40681851 |
| RTN1_1765 | TCGAGTTGGATAGCGAGTTTA | CGCTAAACTTCATCGAAAATAAATCC | chr14:60193921-60194023 |
| mir-1225_1771 | GTAGTTACGTTTCGTGCGTTA | CTAAACGTAAACTACCCCGAAC | chr16:2140686-2140801 |
| mir-3177_1799 | AGTGTAAACGTTAGGTAGTGTTTTC | AAAACAACGCCTAACACGTAT | chr16:1784907-1785023 |
| TGFBI_1805 | TCGTTTCGTTTTATGGCGT | TTAACGAAACCCGCCAAAA | chr5:135364732-135364824 |
| TGFBI_1809 | TTGTACGGGTCGGTTTAGT | ACGAACAAACGAACGACTC | chr5:135364587-135364707 |



LC480 results



| DNA | Type | GNAS_1532 | COL6A3_1719 | TRIM36_1727 | SHOX2_1738 | RTN1_1765 | C3orf70_1749 | ANKRD43_ 1611 | PCDHA6_ 16211 | GRB10_1759 | APOE_1643 | mir-1225_1771 | mir-3177_1799 | TGFBI_1805 | TGFBI_1809 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMR-32 | CL | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| SK-N-AS | CL | 🟩 | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| SH-SY5Y | CL | 🟩 | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 5 | HR-DOD | 🟦 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 41 | HR-DOD | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 384 | HR-DOD | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 513 | HR-DOD | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 610 | HR-DOD | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 906 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 917 | HR-DOD | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 928 | HR-DOD | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1015 | HR-DOD | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1378 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1467 | HR-DOD | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1473 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1477 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 1507 | HR-DOD | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1517 | HR-DOD | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1520 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 |
| 1522 | HR-DOD | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1527 | HR-DOD | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 1648 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1781 | HR-DOD | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2859 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2865 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2866 | HR-DOD | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2869 | HR-DOD | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| E061 | HR-DOD | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E069 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E282 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E290 | HR-DOD | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 526 | HR-SURV | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 915 | HR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1017 | HR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 |
| 1148 | HR-SURV | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1384 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1385 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1431 | HR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1501 | HR-SURV | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1508 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1521 | HR-SURV | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 |
| 1524 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1647 | HR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1789 | HR-SURV | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1793 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1794 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1800 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 2855 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 2856 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2857 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2860 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 2861 | HR-SURV | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2862 | HR-SURV | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 2863 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2864 | HR-SURV | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 2867 | HR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E458 | HR-SURV | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E579 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E598 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E685 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| E700 | HR-SURV | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 410 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 414 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 530 | LR-SURV | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 566 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 744 | LR-SURV | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 809 | LR-SURV | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 820 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 822 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 823 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 858 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 912 | LR-SURV | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 |
| 916 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 926 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 929 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1028 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 1038 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1377 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1395 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1468 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1476 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 1478 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1479 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1486 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1487 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1488 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟦 |
| 1492 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1528 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1531 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1612 | LR-SURV | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1650 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| 1039 | LR-SURV | 🟩 | 🟦 | 🟩 | 🟩 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟦 | 🟦 | 🟦 | 🟩 | 🟩 |
| DKO-U | Neg | 🟩 | 🟦 | 🟩 | 🟩 | 🟦 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 | 🟦 | 🟦 | 🟩 | 🟩 |
| dH2O | NTC | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 | 🟩 |

🟦 Methylated
🟩 Unmethylated

LC480 results

| **Gene** | **HR-DOD** | **HR-SURV** | **LR-SURV** | **Overall** |
|---|---|---|---|---|
| *COL6A3* | 28/28 (100%) | 30/30 (100%) | 30/31 (97%) | 88/89 (99%) |
| miR-1225 | 28/28 (100%) | 30/30 (100%) | 30/31 (97%) | 88/89 (99%) |
| miR-3177 | 28/28 (100%) | 30/30 (100%) | 30/31 (97%) | 88/89 (99%) |
| *PCDHA6* | 27/28 (96%) | 30/30 (100%) | 30/31 (97%) | 87/89 (98%) |
| *PLXNC1* | 28/28 (100%) | 30/30 (100%) | 28/31 (90%) | 86/89 (97%) |
| *ANKRD43* | 28/28 (100%) | 28/30 (93%) | 26/31 (84%) | 82/89 (92%) |
| *ADRB2* | 24/28 (86%) | 28/30 (93%) | 28/31 (90%) | 80/89 (90%) |
| *APOE* | 26/28 (93%) | 28/30 (93%) | 26/31 (84%) | 80/89 (90%) |
| miR-671 | 21/28 (75%) | 22/30 (73%) | 27/31 (87%) | 70/89 (79%) |
| *QPCT* | 24/28 (86%) | 25/30 (83%) | 18/31 (58%) | 67/89 (75%) |
| *KCND2* | 18/28 (64%) | 22/30 (73%) | 23/31 (74%) | 63/89 (71%) |
| *PRPH* | 19/28 (68%) | 24/30 (80%) | 14/31 (45%) | 57/89 (64%) |
| *KRT19 (assay 83159)* | 18/28 (64%) | 20/30 (67%) | 12/31 (39%) | 50/89 (56%) |
| *TNFRSF10D* | 18/28 (64%) | 17/30 (57%) | 10/31 (32%) | 45/89 (51%) |
| *PDLIM4* | 16/28 (57%) | 14/30 (47%) | 12/31 (39%) | 42/89 (47%) |
| *TRIM36* | 11/28 (39%) | 9/30 (30%) | 12/31 (39%) | 32/89 (36%) |
| *GRB10* | 11/28 (39%) | 13/30 (43%) | 6/31 (19%) | 30/89 (34%) |
| *RARRES1* | 12/28 (43%) | 11/30 (37%) | 5/31 (16%) | 28/89 (31%) |
| *GNAS* | 12/28 (43%) | 9/30 (30%) | 3/31 (10%) | 24/89 (27%) |
| *KRT19 (assay 61596)* | 9/28 (32%) | 14/30 (47%) | 0/31 (0%) | 23/89 (26%) |
| *CNR1* | 10/28 (36%) | 10/30 (33%) | 2/31 (6%) | 22/89 (25%) |
| *ACSS3* | 7/28 (25%) | 14/30 (47%) | 0/31 (0%) | 21/89 (24%) |
| *TNFRSF10A* | 8/28 (29%) | 6/30 (20%) | 4/31 (13%) | 18/89 (20%) |
| *TGFBI (assay 1809)* | 6/28 (21%) | 5/30 (17%) | 6/31 (19%) | 17/89 (19%) |
| *FAS* | 6/28 (21%) | 8/30 (27%) | 1/31 (3%) | 15/89 (17%) |
| *SHOX2* | 7/28 (25%) | 5/30 (17%) | 3/31 (10%) | 15/89 (17%) |
| *PTGER4* | 5/28 (18%) | 6/30 (20%) | 3/31 (10%) | 14/89 (16%) |
| *TGFBI (assay 18014)* | 4/28 (14%) | 6/30 (20%) | 3/31 (10%) | 13/89 (15%) |
| *NPTX2* | 4/28 (14%) | 5/30 (17%) | 4/31 (13%) | 13/89 (15%) |
| *HIST1H3C* | 6/28 (21%) | 2/30 (7%) | 0/31 (0%) | 8/89 (9%) |
| *PPIC* | 1/28 (4%) | 2/30 (7%) | 4/31 (13%) | 7/89 (8%) |
| *DPP4* | 4/28 (14%) | 1/30 (3%) | 1/31 (3%) | 6/89 (7%) |
| miR-663 | 2/28 (7%) | 2/30 (7%) | 0/31 (0%) | 4/89 (4%) |
| *CYGB* | 2/28 (7%) | 1/30 (3%) | 0/31 (0%) | 3/89 (3%) |
| *NPY* | 2/28 (7%) | 1/30 (3%) | 0/31 (0%) | 3/89 (3%) |
| *TGFBI (assay 1805)* | 1/28 (4%) | 2/30 (7%) | 0/31 (0%) | 3/89 (3%) |
| *PDE4DIP* | 1/28 (4%) | 1/30 (3%) | 0/31 (0%) | 2/89 (2%) |
| *RTN1* | 0/28 (0%) | 1/30 (3%) | 1/31 (3%) | 2/89 (2%) |
| *CXCR4* | 0/28 (0%) | 0/30 (0%) | 1/31 (3%) | 1/89 (1%) |
| *RBP1* | 0/28 (0%) | 1/30 (3%) | 0/31 (0%) | 1/89 (1%) |
| *EDNRB* | 0/28 (0%) | 1/30 (3%) | 0/31 (0%) | 1/89 (1%) |
| *FBN2 (assay 18150)* | 0/28 (0%) | 0/30 (0%) | 0/31 (0%) | 0/89 (0%) |
| *RBP4* | 0/28 (0%) | 0/30 (0%) | 0/31 (0%) | 0/89 (0%) |
| *FBN2 (assay 18151)* | 0/28 (0%) | 0/30 (0%) | 0/31 (0%) | 0/89 (0%) |
| *NTRK1* | 0/28 (0%) | 0/30 (0%) | 0/31 (0%) | 0/89 (0%) |
| *NEBL* | 0/28 (0%) | 0/30 (0%) | 0/31 (0%) | 0/89 (0%) |
| *C3orf70* | 0/28 (0%) | 0/30 (0%) | 0/31 (0%) | 0/89 (0%) |

LC480 overview results

| **Type** | **Stage** | ***MYCN*** | **Age at diagnosis** | ***TNFRSF10D*** | ***KRT19*** | ***FAS*** | ***PRPH*** | ***CNR1*** | ***QPCT*** | ***HIST1H3C*** | ***ACSS3*** | ***GNAS*** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **HR-DOD** | 3 | amplified | > 12 months | 2/3 (67%) | 2/3 (67%) | 0/3 (0%) | 3/3 (100%) | 2/3 (67%) | 3/3 (100%) | 1/3 (33%) | 1/3 (33%) | 0/3 (0%) |
| | 4 | single copy | > 12 months | 9/11 (82%) | 3/11 (27%) | 0/11 (0%) | 4/11 (36%) | 2/11 (18%) | 9/11 (82%) | 0/11 (0%) | 0/11 (0%) | 6/11 (55%) |
| | | amplified | > 12 months | 6/10 (60%) | 3/10 (30%) | 6/10 (60%) | 9/10 (90%) | 4/10 (40%) | 10/10 (100%) | 5/10 (50%) | 6/10 (60%) | 5/10 (50%) |
| | | | < 12 months | 1/4 (25%) | 1/4 (25%) | 0/4 (0%) | 3/4 (75%) | 2/4 (50%) | 2/4 (50%) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| *Total HR-DOD* | | | | *18/28 (64%)* | *9/28 (32%)* | *6/28 (21%)* | *19/28 (68%)* | *10/28 (36%)* | *24/28 (86%)* | *6/28 (21%)* | *7/28 (25%)* | *12/28 (43%)* |
| **HR-SURV** | 2 | amplified | > 12 months | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| | | | < 12 months | 1/2 (50%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| | 3 | amplified | > 12 months | 5/13 (39%) | 7/13 (54%) | 4/13 (31%) | 9/13 (69%) | 7/13 (54%) | 12/13 (92%) | 2/13 (15%) | 8/13 (62%) | 3/13 (23%) |
| | 4 | single copy | > 12 months | 6/7 (86%) | 4/7 (57%) | 1/7 (14%) | 5/7 (71%) | 1/7 (14%) | 3/7 (43%) | 0/7 (0%) | 2/7 (29%) | 2/7 (29%) |
| | | | < 12 months | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| | | amplified | > 12 months | 2/5 (40%) | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) | 1/5 (20%) | 5/5 (100%) | 0/5 (0%) | 3/5 (60%) | 2/5 (40%) |
| | | | < 12 months | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| *Total HR-SURV* | | | | *17/30 (57%)* | *14/30 (48%)* | *8/30 (27%)* | *24/30 (80%)* | *10/30 (33%)* | *25/30 (83%)* | *2/30 (7%)* | *14/30 (47%)* | *9/30 (30%)* |
| **LR-SURV** | 1 | single copy | > 12 months | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| | | | < 12 months | 8/20 (40%) | 0/20 (0%) | 0/20 (0%) | 7/20 (35%) | 1/20 (5%) | 12/20 (60%) | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| | 2 | single copy | > 12 months | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| | | | < 12 months | 1/7 (14%) | 0/7 (0%) | 1/7 (14%) | 5/7 (71%) | 1/7 (14%) | 3/7 (43%) | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| | 3 | single copy | < 12 months | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| *Total LR-SURV* | | | | *10/31 (32%)* | *0/31 (0%)* | *1/31 (3%)* | *14/31 (45%)* | *2/31 (6%)* | *18/31 (58%)* | *0/31 (0%)* | *0/31 (0%)* | *3/31 (10%)* |
| ***Overall total*** | | | | ***45/89 (51%)*** | ***23/89 (26%)*** | ***15/89 (17%)*** | ***57/89 (64%)*** | ***22/89 (25%)*** | ***67/89 (75%)*** | ***8/89 (9%)*** | ***21/89 (24%)*** | ***24/89 (27%)*** |

Group associations

| **Type** | **Stage** | ***MYCN*** | **Age at diagnosis** | ***TGFBI*** | ***TNFRSF10D*** | ***KRT19*** | ***TNFRSF10A*** | ***RARRES1*** | ***FAS*** | ***PRPH*** | ***CNR1*** | ***QPCT*** | ***HIST1H3C*** | ***ACSS3*** | ***GNAS*** | ***GRB10*** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Stage** | 1 | Single copy | > 12 months | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (100%) | 0/1 (100%) | 0/1 (0%) | 0/1 (0%) |
| | | | < 12 months | 2/20 (10%) | 8/20 (40%) | 0/20 (0%) | 3/20 (15%) | 4/20 (20%) | 0/20 (0%) | 7/20 (35%) | 1/20 (5%) | 12/20 (60%) | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) | 4/20 (20%) |
| | *Stage 1* | | | *3/21 (14%)* | *9/21 (43%)* | *0/21 (0%)* | *3/21 (14%)* | *4/21 (19%)* | *0/21 (0%)* | *8/21 (38%)* | *1/21 (5%)* | *13/21 (62%)* | *0/21 (0%)* | *0/21 (0%)* | *2/21 (10%)* | *4/21 (19%)* |
| | 2 | Single copy | > 12 months | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) | 1/2 (50%) |
| | | | < 12 months | 0/7 (100%) | 1/7 (14%) | 0/7 (0%) | 1/7 (14%) | 1/7 (14%) | 1/7 (14%) | 5/7 (71%) | 1/7 (14%) | 3/7 (43%) | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) | 1/7 (14%) |
| | | Amplified | > 12 months | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| | | | < 12 months | 0/2 (0%) | 1/2 (0%) | 0/2 (0%) | 1/2 (50%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| | *Stage 2* | | | *1/12 (8%)* | *3/12 (25%)* | *1/12 (8%)* | *2/12 (17%)* | *1/12 (8%)* | *2/12 (17%)* | *8/12 (67%)* | *2/12 (17%)* | *8/12 (67%)* | *0/12 (0%)* | *1/12 (8%)* | *2/12 (17%)* | *3/12 (25%)* |
| | 3 | Single copy | < 12 months | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| | | Amplified | > 12 months | 6/16 (38%) | 7/16 (44%) | 9/16 (56%) | 6/16 (38%) | 7/16 (44%) | 4/16 (25%) | 12/16 (75%) | 9/16 (56%) | 15/16 (94%) | 3/16 (19%) | 9/16 (56%) | 3/16 (19%) | 8/16 (50%) |
| | *Stage 3* | | | *6/17 (35%)* | *7/17 (41%)* | *9/17 (53%)* | *6/17 (35%)* | *7/17 (41%)* | *4/17 (24%)* | *13/17 (77%)* | *9/17 (53%)* | *15/17 (88%)* | *3/17 (18%)* | *9/17 (58%)* | *3/17 (18%)* | *8/17 (47%)* |
| | 4 | Single copy | > 12 months | 0/18 (0%) | 15/18 (83%) | 7/18 (39%) | 1/18 (6%) | 11/18 (61%) | 1/18 (6%) | 9/18 (50%) | 3/18 (17%) | 12/18 (67%) | 0/18 (0%) | 2/18 (11%) | 8/18 (44%) | 8/18 (44%) |
| | | | < 12 months | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) |
| | | Amplified | > 12 months | 3/15 (20%) | 8/15 (53%) | 4/15 (27%) | 6/15 (40%) | 4/15 (27%) | 8/15 (53%) | 14/15 (93%) | 5/15 (33%) | 15/15 (100%) | 5/15 (33%) | 9/15 (60%) | 7/15 (47%) | 6/15 (40%) |
| | | | < 12 months | 0/5 (0%) | 2/5 (40%) | 2/5 (40%) | 0/5 (0%) | 1/5 (20%) | 0/6 (0%) | 4/5 (80%) | 2/5 (40%) | 3/5 (60%) | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) | 1/5 (20%) |
| | *Stage 4* | | | *3/39 (7%)* | *26/39 (67%)* | *13/39 (33%)* | *7/39 (18%)* | *16/39 (41%)* | *9/39 (15%)* | *28/39 (72%)* | *10/39 (26%)* | *31/39 (80%)* | *5/39 (18%)* | *11/39 (28%)* | *17/39 (44%)* | *15/39 (39%)* |
| ***MYCN*** | *MYCN single copy* | | | *3/50 (6%)* | *26/50 (52%)* | *7/50 (14%)* | *5/50 (10%)* | *16/50 (32%)* | *2/50 (4%)* | *24/50 (48%)* | *5/50 (10%)* | *31/50 (62%)* | *0/50 (0%)* | *2/50 (4%)* | *12/50 (24%)* | *14/50 (28%)* |
| | *MYCN amplified* | | | *10/39 (26%)* | *19/39 (49%)* | *16/39 (41%)* | *13/39 (33%)* | *12/39 (31%)* | *13/39 (33%)* | *33/39 (85%)* | *17/39 (44%)* | *36/39 (92%)* | *8/39 (21%)* | *19/39 (49%)* | *12/39 (31%)* | *16/39 (41%)* |
| **Age** | *Age at diagnosis > 12 months* | | | *11/53 (21%)* | *32/53 (60%)* | *21/53 (40%)* | *13/53 (25%)* | *22/53 (42%)* | *14/53 (26%)* | *37/53 (69%)* | *18/53 (34%)* | *46/53 (87%)* | *8/53 (15%)* | *21/53 (40%)* | *20/53 (38%)* | *24/53 (45%)* |
| | *Age at diagnosis < 12 months* | | | *2/36 (6%)* | *13/36 (36%)* | *2/36 (6%)* | *5/36 (14%)* | *6/36 (17%)* | *1/36 (3%)* | *20/396(56%)* | *4/36 (11%)* | *21/36 (58%)* | *0/36 (0%)* | *0/36 (0%)* | *4/36 (11%)* | *6/36 (17%)* |
| | *Age at diagnosis > 18 months* | | | *9/45 (20%)* | *27/45 (60%)* | *20/45 (44%)* | *11/45 (24%)* | *19/45 (42%)* | *13/45 (29%)* | *33/45 (73%)* | *17/45 (38%)* | *40/45 (89%)* | *8/45 (18%)* | *19/45 (49%)* | *18/45 (40%)* | *23/45 (51%)* |
| | *Age at diagnosis < 18 months* | | | *4/44 (9%)* | *18/44 (41%)* | *3/44 (7%)* | *7/44 (16%)* | *9/44 (20%)* | *2/44 (5%)* | *24/44 (55%)* | *5/44 (11%)* | *27/44 (61%)* | *0/44 (0%)* | *2/44 (5%)* | *6/44 (14%)* | *7/44 (16%)* |
| ***Overall total*** | | | | ***13/89 (15%)*** | ***45/89 (51%)*** | ***23/89 (26%)*** | ***18/89 (20%)*** | ***28/89 (32%)*** | ***15/89 (17%)*** | ***57/89 (64%)*** | ***22/89 (25%)*** | ***67/89 (75%)*** | ***8/89 (9%)*** | ***21/89 (24%)*** | ***24/89 (27%)*** | ***30/89 (34%)*** |

Risk factor associations


Methylated
Unmethylated
group 1
group 2
HR-SURV
HR-DOD
LR-SURV
PPIC_69739
DPP4_74913
CYGB_83388
NPY_18477
mir663_1705
PDE4DIP_1689
TGFBI_1805
RTN1_1765
EDNRB_1
RBP1_83281
C3orf70_1749
NEBL_1678
NTRK1_1259
FBN2_18151
FBN2_18150
RBP4_24106
CXCR4_70046
TRIM36_1727
RARRES1_57581
GNAS_1532
GRB10_1759
CNR1_1699
SHOX2_1738
KRT19_61596
TGFBI_18014
ACSS3_1504
HIST1H3C_1491
FAS_18143
NPTX2_57773
PTGER4_1659
TGFBI_1809
TNFRSF10A_65529
PD□IM4_4
TNFRSF10D_23780
KRT19_83159
PRPH_1409
QPCT_1446
KCND2_1525
mir671_job1465
ADRB2_1431
APOE_1643
ANKRD43_1611
PLXNC1_1397
PCDHA6_16211
mir3177_1799
COL6A3_1719
mir1225_1771
sample1479
sample2866
sample822
sample1650
sample1378
sample1487
sample526
sample2864
sample1521
sample1781
sample1794
sample2861
sample610
sample1522
sample1385
sample906
sample929
sample1486
sample915
sample1017
sample1520
sample1384
sample513
sample1527
sample1477
sample2862
sample1431
sample917
sample5
sample1148
sampleE069
sample2859
sample2857
sample1524
sample2856
sample2860
sample1800
sample384
sample928
sample1517
sample41
sample1501
sample1507
sample1473
sample1039
sample820
sample1476
sample823
sample2855
sample744
sample2869
sample1647
sample1528
sample1488
sample1377
sample1468
sample1478
sampleE061
sample1467
sample1789
sample809
sample1612
sample1531
sample566
sample1492
sample414
sample2867
sample858
sample1038
sample916
sample1395
sample926
sampleE685
sample1015
sampleE579
sample530
sample1028
sample410
sample1648
sample912
sample2865
sampleE598
sampleE290
sample1793
sampleE282
sample2863
sampleE700
sampleE458
sample1508

Heatmap



1.0
0.8
0.6
0.4
0.2
0.0
Overall survival
0-16 methylation events
p=0.01
16-27 methylation events
0
1000
2000
3000
4000
5000
Days

KM number